No Data
Keymed Biosciences Inc. (HKG:2162) Looks Just Right With A 28% Price Jump
Press Release: Keymed Biosciences Announces Annual Results of 2024
[Brokerage Focus] BOCOM INTL maintains a Buy rating on Cannae (02162), pointing out that the prospects for early pipeline business development overseas remain promising.
Jingwu Financial News | BOCOM INTL research report indicates that in 2024, Kangnuo Ya (02162) is expected to have revenues of 0.428 billion yuan (same unit below), a year-on-year increase of 21%. Among them, cooperative revenue is 0.392 billion yuan, mainly from licensing income of CM512, CM536, and CM336, as well as subsequent revenue from the collaboration on CMG901; initial sales revenue of Kangyueda (Sipuqibai monoclonal antibody) after launch is 0.036 billion yuan. The annual net loss is expected to be 0.515 billion yuan, a widening from last year's loss of 0.359 billion yuan, mainly due to increased R&D and sales expenses driven by pipeline advancement and business expansion. The bank expects Kangyueda.
Keymed Biosciences Widens Loss in 2024
KEYMED BIO-B (02162.HK) is expected to have a revenue of 0.428 billion yuan in 2024, with a year-on-year growth of 21%.
On March 24, Gelonghui reported that KEYMED BIO-B (02162.HK) announced its annual results for the year ended December 31, 2024, with revenue of RMB 0.428 billion, a year-on-year increase of 21%; gross profit of RMB 0.416 billion, a year-on-year increase of 31%; annual loss of RMB 0.515 billion compared to a loss of RMB 0.357 billion in the same period last year. As of December 31, 2024, the total amount of cash and cash equivalents, time deposits, and bank wealth management products was RMB 2.156 billion.
KEYMED BIO-B (02162) released the 2024 fiscal year results, with a loss attributable to Shareholders of 0.515 billion yuan, an increase of 43.4% year-on-year.
KEYMED BIO-B (02162) announced its annual performance for the year ending December 31, 2024, with revenue of 0.428 billion yuan...
